Insider Selling: Keros Therapeutics (NASDAQ:KROS) Director Sells 2,625 Shares of Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Julius Knowles sold 2,625 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the sale, the director owned 10,958 shares in the company, valued at approximately $117,579.34. This trade represents a 19.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keros Therapeutics Stock Down 2.9%

NASDAQ KROS traded down $0.30 during trading hours on Monday, hitting $10.00. 169,361 shares of the company were exchanged, compared to its average volume of 378,172. The company has a 50 day moving average of $11.33 and a two-hundred day moving average of $15.15. Keros Therapeutics, Inc. has a 52-week low of $9.79 and a 52-week high of $22.55. The firm has a market cap of $197.92 million, a price-to-earnings ratio of -3.32 and a beta of 0.94.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.19). Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.The company had revenue of $0.37 million for the quarter, compared to analysts’ expectations of $1.93 million. On average, equities research analysts predict that Keros Therapeutics, Inc. will post -5.19 EPS for the current year.

Hedge Funds Weigh In On Keros Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC increased its stake in shares of Keros Therapeutics by 1,420.6% during the 4th quarter. SG Americas Securities LLC now owns 98,703 shares of the company’s stock worth $2,010,000 after purchasing an additional 92,212 shares in the last quarter. Western Standard LLC increased its stake in shares of Keros Therapeutics by 42.7% during the 3rd quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock worth $34,644,000 after purchasing an additional 654,989 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of Keros Therapeutics by 260.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 171,941 shares of the company’s stock worth $2,720,000 after purchasing an additional 124,287 shares in the last quarter. Massachusetts Financial Services Co. MA purchased a new position in shares of Keros Therapeutics during the 4th quarter worth approximately $890,000. Finally, Abacus Wealth Partners LLC purchased a new position in shares of Keros Therapeutics during the 4th quarter worth approximately $287,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on KROS. Wells Fargo & Company lowered their price objective on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, March 5th. Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings cut Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Three research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Keros Therapeutics has an average rating of “Hold” and an average target price of $20.40.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.